Johns Hopkins researchers closely tracked the genetic evolution of one man’s metastatic prostate cancer over seven years. Their work revealed how a small group of resistant cells grew to drive the cancer’s progression — and ultimately pointed to a targeted therapy that worked when other treatments failed.
